Administration of cinacalcet, an alternative ligand of calcium-sensing receptor decreasing the production of parathyroid hormone and thereby lowering serum calcium and phosphate, to the patients with chronic kidney disease reduced the risk of major adverse cardiovascular events [59]. This evidence concerns the gene PTH and chronic kidney disease.